In a mouse model of alcoholic fatty liver disease, RGZ treatment activated the hepatic Sirt1-AMPK signaling pathway, resulting in increased fatty acid oxidation and inhibited lipogenesis in the liver [18]. Here, SIRT1 is linked to alcoholic fatty liver disease.